MICOT PHARMA-B (02335) Completes Data Lock for Phase II Clinical Trial of MT200605 in Acute Ischemic Stroke (AIS)

Stock News07-24

MICOT PHARMA-B (02335) has announced that the Phase II clinical trial for its candidate drug MT200605, designed to treat acute ischemic stroke, has successfully completed database locking.

MT200605 is an injectable neuroprotective agent featuring a dual synergistic mechanism of action. It is engineered to simultaneously activate TrkB receptors and eliminate oxygen free radicals. This approach helps inhibit neuronal apoptosis, reduce excitotoxicity, and alleviate inflammatory responses, thereby minimizing cell death. Additionally, it works by reactivating the endogenous repair mechanisms of neurons upstream, improving synaptic plasticity and promoting neuronal regeneration.

The Phase II clinical trial for MT200605 in acute ischemic stroke, conducted in China, was a multicenter, randomized, double-blind, placebo-controlled study. Its primary objectives were to evaluate the efficacy, safety, and pharmacokinetics of MT200605. The trial enrolled its first patient in September 2025, completed enrollment of all 360 patients in March 2026, finished the last patient's follow-up in June 2026, and recently achieved database locking.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1142184840?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-24 19:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142184840","market":"hk","top_or_hot":-1,"title":"MICOT PHARMA-B (02335) Completes Data Lock for Phase II Clinical Trial of MT200605 in Acute Ischemic Stroke (AIS)","media":"Stock News","content":"<p><b>MICOT PHARMA-B (02335)</b> has announced that the Phase II clinical trial for its candidate drug MT200605, designed to treat acute ischemic stroke, has successfully completed database locking.<br><br>MT200605 is an injectable neuroprotective agent featuring a dual synergistic mechanism of action. It is engineered to simultaneously activate TrkB receptors and eliminate oxygen free radicals. This approach helps inhibit neuronal apoptosis, reduce excitotoxicity, and alleviate inflammatory responses, thereby minimizing cell death. Additionally, it works by reactivating the endogenous repair mechanisms of neurons upstream, improving synaptic plasticity and promoting neuronal regeneration.<br><br>The Phase II clinical trial for MT200605 in acute ischemic stroke, conducted in China, was a multicenter, randomized, double-blind, placebo-controlled study. Its primary objectives were to evaluate the efficacy, safety, and pharmacokinetics of MT200605. The trial enrolled its first patient in September 2025, completed enrollment of all 360 patients in March 2026, finished the last patient's follow-up in June 2026, and recently achieved database locking.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MICOT PHARMA-B (02335) Completes Data Lock for Phase II Clinical Trial of MT200605 in Acute Ischemic Stroke (AIS)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMICOT PHARMA-B (02335) Completes Data Lock for Phase II Clinical Trial of MT200605 in Acute Ischemic Stroke (AIS)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-24 19:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>MICOT PHARMA-B (02335)</b> has announced that the Phase II clinical trial for its candidate drug MT200605, designed to treat acute ischemic stroke, has successfully completed database locking.<br><br>MT200605 is an injectable neuroprotective agent featuring a dual synergistic mechanism of action. It is engineered to simultaneously activate TrkB receptors and eliminate oxygen free radicals. This approach helps inhibit neuronal apoptosis, reduce excitotoxicity, and alleviate inflammatory responses, thereby minimizing cell death. Additionally, it works by reactivating the endogenous repair mechanisms of neurons upstream, improving synaptic plasticity and promoting neuronal regeneration.<br><br>The Phase II clinical trial for MT200605 in acute ischemic stroke, conducted in China, was a multicenter, randomized, double-blind, placebo-controlled study. Its primary objectives were to evaluate the efficacy, safety, and pharmacokinetics of MT200605. The trial enrolled its first patient in September 2025, completed enrollment of all 360 patients in March 2026, finished the last patient's follow-up in June 2026, and recently achieved database locking.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AIS","symbol_name":"VistaShares Artificial Intelligence Supercycle ETF","start_time":0,"source_url":"","article_id":"1142184840","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142184840","pubTimestamp":1784893701,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"MICOT PHARMA-B (02335) has announced that the Phase II clinical trial for its candidate drug MT200605, designed to treat acute ischemic stroke, has successfully completed database locking.MT200605 is...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AIS":"VistaShares Artificial Intelligence Supercycle ETF","MDTX":"Corgi MediaTek 2x Daily ETF","BMED":"iShares Health Innovation Active ETF","02335":"麦科医药-B","BK1161":"生物科技","PSYK":"PSYK ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF"},"translate_title":"MICOT PHARMA-B (02335) 完成 MT200605 急性缺血性卒中 (AIS) II 期临床试验的数据锁定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBBQ":1,"BMED":1,"MDTX":1,"PSYK":1,"02335":1,"IBBJ":1,"AIS":1},"content_text":"MICOT PHARMA-B (02335) has announced that the Phase II clinical trial for its candidate drug MT200605, designed to treat acute ischemic stroke, has successfully completed database locking.MT200605 is an injectable neuroprotective agent featuring a dual synergistic mechanism of action. It is engineered to simultaneously activate TrkB receptors and eliminate oxygen free radicals. This approach helps inhibit neuronal apoptosis, reduce excitotoxicity, and alleviate inflammatory responses, thereby minimizing cell death. Additionally, it works by reactivating the endogenous repair mechanisms of neurons upstream, improving synaptic plasticity and promoting neuronal regeneration.The Phase II clinical trial for MT200605 in acute ischemic stroke, conducted in China, was a multicenter, randomized, double-blind, placebo-controlled study. Its primary objectives were to evaluate the efficacy, safety, and pharmacokinetics of MT200605. The trial enrolled its first patient in September 2025, completed enrollment of all 360 patients in March 2026, finished the last patient's follow-up in June 2026, and recently achieved database locking.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1142184840","isCrawlerRequest":true}